*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

The latest news about OXLUMO® (lumasiran) is just a few clicks away

Sign up today to receive relevant communications and content about PH1 and OXLUMO.

I am: (select one)

Diagnosed With PH1

Caregiver

Curious About PH1

Medical Professional

Other

Please select what describes you best

I describe myself as a:

*Please select a description

I describe myself as a:

*Please select a description

*Please enter your first name

*Please enter your last name

*Please enter your email address

*This email address is already in use

*Please enter your ZIP / postal code

I am 18 years old or older, a US resident, and would like to receive PH1 and OXLUMO updates from Alnylam Pharmaceuticals.

By submitting this form, I agree to the Alnylam Privacy Policy and consent to the processing of my personal data per the terms outlined in the Data Privacy Notification and Consent.

email_update

IMPORTANT SAFETY INFORMATION

The most common side effect of OXLUMO® (lumasiran) is injection site reaction (redness, swelling, pain, bruising, itching, and discoloration at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

WHAT IS OXLUMO?

OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine and blood in children and adults.

For additional information about OXLUMO, please see full Prescribing Information.